큐라클
Financials
Valuation Metrics
큐라클's Market Cap is ₩2025B. At end of 2025 it was ₩1580B. Ranked #849 of 2,421 in KR market (top 35%), #395 of 1,640 on KOSDAQ (top 24%), #89 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 39%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 202.51B KRW | KR#849/2,421 Sec#89/231 |
| Revenue | 7.1M KRW | KR#2,395/2,421 Sec#226/231 |
| Net Income | -7.59B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 59.45B KRW | KR#2,112/2,421 Sec#184/231 |
| Net Assets | 46.70B KRW | KR#1,953/2,421 Sec#164/231 |
| Employees | 32 | KR#2,191/2,421 Sec#203/231 |
| Value | ||
| P/B | 4.34x | KR#2,211/2,421 Sec#186/231 |
| P/S | 28517.33x | KR#2,414/2,421 Sec#228/231 |
| FCF Yield | -6.64% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -16.25% | KR#2,046/2,421 Sec#158/231 |
| ROA | -12.76% | KR#2,155/2,421 Sec#165/231 |
| Op. Margin | -115180.17% | KR#2,394/2,421 Sec#225/231 |
| Revenue Growth | -99.56% | KR#2,328/2,421 Sec#211/231 |
| Financial Health | ||
| Debt Ratio | 27.30% | KR#532/2,421 Sec#59/231 |
| Total Debt | 11.00B KRW | KR#1,587/2,421 Sec#141/231 |
| FCF | -13.45B KRW | KR#1,794/2,421 Sec#161/231 |
| Cash | 9.90B KRW | KR#1,705/2,421 Sec#145/231 |
| Current Ratio | 1.94x | KR#902/2,421 Sec#101/231 |
| Performance | ||
| 1Y Return | 64.98% | KR#209/2,421 Sec#6/231 |
| 1M Return | -16.07% | KR#2,257/2,421 Sec#194/231 |
| From 52W High | -55.95% | KR#1,698/2,421 Sec#129/231 |
| 1Y MDD | -63.12% | KR#1,651/2,421 Sec#136/231 |
| Trading | ||
| Volume | 39,816 shares | KR#1,244/2,421 Sec#121/231 |
| Trading Value | 367.3M KRW | KR#1,056/2,421 Sec#107/231 |
| Foreign Own. | 1.78% | KR#1,711/2,421 Sec#165/231 |
| Per Share | ||
| EPS | -342 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,108 KRW | KR#2,046/2,421 Sec#170/231 |
Company Info
Established in 2016, this company is a specialized bio-venture focusing on research and development of therapeutics for endothelial dysfunction, specially listed on KOSDAQ in 2021. It builds an innovative new drug pipeline and conducts research and development based on its proprietary new drug development platforms, Solvadis and Eagles. In 2024, Rivasterat demonstrated vision improvement in a US Phase 2a clinical trial, while CU01 is expanding its portfolio through joint research and development and completion of domestic Phase 2b patient recruitment in 2025. Curacle, established in 2016, is headquartered in Seoul Metropolitan City, Seocho-gu.